Boule Diagnostics AB (publ) (BOUL.ST)

Sweden · Healthcare · SEK

Key financials

ROE: -2.06%; 2025 (actual)
ROA: -0.76%; 2025 (actual)
Gross Margin: 43.66%; 2025 (actual)
Net Margin: -0.77%; 2025 (actual)
Total Assets: SEK 469.56M; 2025 (actual)
Net Income: -SEK 3.75M; 2025 (actual)
Valuation: -
Stock Price: SEK 4.91; 2025 (actual)

Historical & projected performance

Reported figures and Equlion model projections for the next 5 years.

Metric	2025 (actual)	2026	2027	2028	2029	2030
Gross Margin	43.66%	43.66%	43.66%	43.66%	43.66%	43.66%
Sector average	16.85%	17.71%	17.71%	17.71%	17.71%	17.71%
Total Assets	SEK 469.56M	SEK 464.00M	SEK 472.94M	SEK 527.62M	SEK 579.27M	SEK 610.05M
Sector average	SEK 2,857.19M	SEK 2,900.24M	SEK 3,045.01M	SEK 3,280.29M	SEK 3,536.41M	SEK 3,762.91M
Stock Price	SEK 4.91	SEK 4.91

Amounts in SEK (millions); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Stock price and valuation carry no data date: they are the Equlion model's estimate for 2025. Projections are model estimates, not investment advice.

Want the full financial forecast report for Boule Diagnostics AB (publ)? It covers the balance sheet, income statement and Equlion model projections.